TrialAdvances in therapy2025

Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3115, an Ustekinumab Biosimilar, and EU- and US-Stelara in Healthy Adult Participants: A Randomized, Double-Blind, Single-Dose Study.

Jun Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.